
Merck & Moderna merger/acquisition announced in 2026?
- Volume 24 h
- —
- Volume total
- 467 $
- Liquidité
- 113 $
- Clôture
- 1 janv. 2027
- M&A
- MRK
- MRNA
- Merck
- pharma
- Finance
Oui
16%
Carnet d’ordres
| Prix | Parts |
|---|---|
| 74¢ | 40 |
| 74¢ | 27 |
| 74¢ | 30 |
| 31¢ | 39 |
| 29¢ | 40 |
| 29¢ | 6 |
| Écart 25.4¢ | |
| 3¢ | 29 |
| 3¢ | 9 |
Issues
- Oui— / 24 hhausse sur 24 h +0.9 pts16%
- Non— / 24 h84%
Règles de résolution
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries. An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs. A bid or offer announcement without the indication of a settled agreement will not qualify. Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count. The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.